上海医药(02607)：二羟丙茶碱注射液获得批准生产

Core Viewpoint - Shanghai Pharmaceuticals (02607) has received approval from the National Medical Products Administration for the production of Dihydroxypropyl Theophylline Injection, which is indicated for bronchial asthma, wheezing bronchitis, and obstructive pulmonary emphysema, among other conditions [1] Group 1: Product Approval - The Dihydroxypropyl Theophylline Injection received its drug registration certificate (Certificate No: 2026S00781) [1] - The product is expected to alleviate symptoms of wheezing and can also be used for wheezing caused by cardiogenic pulmonary edema [1] Group 2: Development and Investment - Shanghai Pharmaceuticals' subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., submitted the registration application for this product in October 2024, which was accepted [1] - The company has invested approximately RMB 3.14 million in research and development for this product as of the date of the announcement [1] Group 3: Market Impact - According to national policies, newly registered generic drugs will receive greater support in areas such as medical insurance payments and procurement by medical institutions [1] - The approval for production is expected to enhance the market share and competitiveness of the Dihydroxypropyl Theophylline Injection, while also providing valuable experience for future generic drug applications [1]